OAM
BLFS icon

Oxford Asset Management’s BioLife Solutions BLFS Stock Holding History

Oxford Asset Management’s Portfolio BLFS Stock Details BLFS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-29,836
Closed -$521K – 1787
2018
Q3 		$521K Buy
+29,836
New +$590K 0.01% 1298

Other funds holding BLFS

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
SCM
Sandler Capital Management New York $193M AUM 77.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
CCM
Cadence Capital Management Boston, Massachusetts $415M AUM 11.01% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Oxford Asset Management's BLFS Position: Q4 2018 in Review

Oxford Asset Management sold out of BioLife Solutions (BLFS) in Q4 2018, closing a stake of 29,836 shares — an estimated $521K sold.

Oxford Asset Management first reported a position in BLFS in Q3 2018 and held it in 1 quarter. The position peaked at $521K in Q3 2018. 54 funds tracked by Wall St. Rank hold BLFS as of Q4 2018.

  • Oxford Asset Management reported no remaining BioLife Solutions position as of Q4 2018 after selling out during the quarter.
  • Oxford Asset Management sold 29,836 BioLife Solutions shares in Q4 2018, an estimated $521K.
  • Oxford Asset Management first reported a position in BioLife Solutions in Q3 2018 and held it in 1 quarter.
  • Oxford Asset Management's BioLife Solutions position peaked at $521K in Q3 2018.
  • 54 funds tracked by Wall St. Rank held BioLife Solutions as of Q4 2018.

Based on Oxford Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.